Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2026 | $14.00 | Underweight → Neutral | Piper Sandler |
| 12/9/2025 | $7.50 | Underweight | Barclays |
| 10/27/2025 | $5.00 | Overweight → Underweight | Piper Sandler |
| 5/2/2025 | Outperform → In-line | Evercore ISI | |
| 9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
| 11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
| 9/21/2023 | $28.00 | Overweight | Barclays |
| 3/16/2023 | $33.00 | Outperform | Raymond James |
DEFA14A - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
DEFM14A - Organon & Co. (0001821825) (Filer)
25-year industry leader to drive continued growth and expand access to medicines in CanadaKIRKLAND, QC, July 22, 2026 /CNW/ -- Organon Canada, a global healthcare company dedicated to improving the health of women, is pleased to announce the appointment of Dominic Bégin as President and Managing Director. In this role, Mr. Bégin will lead the organization's strategic and commercial agenda, strengthen its leadership in key therapeutic areas, and expand access to cost-effective solutions, including biosimilars, for governments and payers across Canada. "I am honoured to take on this role and continue building on the strong founda
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly e
New analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD) Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in AD will be presented at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting, taking place July 22 – 25, 2026, in Minneapolis, Minnesota. The presentation includes a pooled post hoc analysis of data from the pivotal Phase 3 ADORING 1 and ADORING 2 clinical trials evaluating the efficacy and safety of VTAMA
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
Piper Sandler upgraded Organon from Underweight to Neutral and set a new price target of $14.00
Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50
Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the second quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly e
Organon (NYSE:OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasiv
First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
25-year industry leader to drive continued growth and expand access to medicines in CanadaKIRKLAND, QC, July 22, 2026 /CNW/ -- Organon Canada, a global healthcare company dedicated to improving the health of women, is pleased to announce the appointment of Dominic Bégin as President and Managing Director. In this role, Mr. Bégin will lead the organization's strategic and commercial agenda, strengthen its leadership in key therapeutic areas, and expand access to cost-effective solutions, including biosimilars, for governments and payers across Canada. "I am honoured to take on this role and continue building on the strong founda
Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o
Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac